Short course treatment for low-level cryptococcal infection in HIV
Part of Brain & nervous system, Infections clinical trials.
This study tests a shorter course of an antifungal medicine (fluconazole) for people with HIV who have a low level of a fungus called cryptococcus in their blood. The goal is to see if a shorter treatment works as well and to find the best time to start HIV medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are living with HIV.
- You are 18 years or older.
- You have a positive blood test for cryptococcus with a low level (titer less than 1:160).
- You have not had a cryptococcal infection before.
- You are not pregnant or breastfeeding.
- You can attend regular clinic visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This trial tests the drug amphotericin B for people with cryptococcal meningitis who do not have HIV. The goal is to see if this treatment is safe and effective.
This trial tests a single high dose of a potent antifungal medicine (liposomal amphotericin B) combined with a modern HIV treatment (B/F/TAF) for people with HIV who have a serious fungal infection called talaromycosis. The goal is to see if this short, powerful treatment works well and is safe.
This study tests whether a shorter course of antifungal medication works as well as the standard longer course for patients with a yeast infection in the blood (candidemia) that is not complicated by spread to other organs. If you have cleared the infection from your blood and are fever-free, you may be able to stop treatment sooner.
This study tests whether a combination of two antifungal drugs works well for treating talaromycosis, a serious fungal infection common in people with HIV. The goal is to find a more convenient and effective treatment.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.